Small Cell Lung Cancer

Status: open

[17-081 - 1031505-3] A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with Extensive Stage Small Cell Lung Cancer (MERU)

Treatment for Lung Cancer

Contact Us Or call (251) 445-9834

Description

This is a Phase 3, randomized, double-blind, placebo-controlled, multinational, and multicenter study to evaluate the efficacy of rovalpituzumab tesirine as maintenance therapy following first-line platinum-based chemotherapy. IRB Number 17-081

Sponsors

This trial is sponsored by AbbVie.

Providers Associated With This Trial

Principle Investigator

Sub Investigators

This link will open in a new tab or window.